Menu

Infographic: Treating Duchenne Muscular Dystrophy with CRISPR

The disease is caused by mutations in a single gene. Can gene editing fix the problem?

Aug 30, 2018
Sandeep Ravindran

Dystrophin is part of a protein complex linking the cytoskeleton of muscle fibers to the surrounding connective tissue (basal lamina). It’s a long protein with numerous redundant coils (purple balls), and acts like a shock absorber during contraction. Without functional dystrophin to support muscle strength and stability, muscle fibers are easily damaged.

© steve graepel

The genetics of Duchenne

Duchenne muscular dystrophy results from mutations in the DMD gene that encodes the dystrophin protein. There are many types of mutations that can cause the disease; each disrupts the reading frame such that translation terminates prematurely, producing no functional dystrophin protein. DMD mutations are particularly common in “hotspot” areas of the gene (exons 45–55 and 2–10).

Wildtype DMD gene

Duchenne-causing mutations

© STEVE GRAEPEL



Because the genetic underpinnings of Duchenne are known, researchers can devise gene-editing fixes to the problem. Several potential treatments are now being tested in preclinical and clinical studies. In some cases, they aim to correct the mutations in the DMD gene; other times, the goal is simply to restore a shorter but still partially functional dystrophin protein.

Example: A mutation in exon 44 disrupts the reading frame and causes translation to stop prematurely, leading to a dysfunctional protein.

Strategies for fixing the problem

© steve graepel

Read the full story.

March 2019

Going Under

Dissecting the effects of anesthetics

Marketplace

Sponsored Product Updates

The Complex Biology of Macrophages: Origins, Functions, and Activation States
The Complex Biology of Macrophages: Origins, Functions, and Activation States
Download this poster from R&D Systems for a detailed overview of macrophage markers, functions, development, specialization, and activation!
A Guide to Measuring Drug-Target Residence Times with Biochemical Assays
A Guide to Measuring Drug-Target Residence Times with Biochemical Assays
Download this guide from BellBrook Labs to learn about how to use Transcreener® biochemical assays to measure drug-target residence times, complete with examples and case studies!
Beckman Coulter Life Sciences To Launch New Product Via Live Stream Event
Beckman Coulter Life Sciences To Launch New Product Via Live Stream Event
After visiting labs around the world to identify ways to advance its industry-leading cell counting technology, Beckman Coulter Life Sciences will host a live streaming event on March 26 at 10 a.m. EDT / 7 a.m. PDT to announce its latest product innovation.  
Cybrexa Therapeutics to Present First Data and Unveil Details for its alphalex™-PARP Inhibitor Lead Candidate CBX-11 at AACR Annual Meeting 2019
Cybrexa Therapeutics to Present First Data and Unveil Details for its alphalex™-PARP Inhibitor Lead Candidate CBX-11 at AACR Annual Meeting 2019
Cybrexa Therapeutics, a biotechnology company developing a new class of cancer therapeutics through its alphalex™ tumor targeting platform, today announced that Vishwas Paralkar, PhD, Chief Scientific Officer of Cybrexa, will present the first set of preclinical data supporting its alphalex™-PARP inhibitor lead candidate, CBX-11, at the American Association for Cancer Research (AACR) Annual Meeting 2019, being held March 29 – April 3 in Atlanta, Georgia. At the meeting, the Company will unveil the FDA-approved poly ADP-ribose polymerase (PARP) inhibitor conjugated in CBX-11.